Bayer Competitors and Similar CompaniesClear all
Bayer's competitors and similar companies include Shionogi, Astellas Pharma, AstraZeneca, Roche, Novartis, Pfizer, GSK and Johnson & Johnson.
 Shionogi Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases. |  Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Roche Roche Holding is a biotech company that provides in-vitro diagnostics and supplies solutions across various disease areas. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  GSK GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. |  Johnson & Johnson Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. | ||
Founding Date | Founding Date 1863 | Founding Date 1878 | Founding Date 1923 | Founding Date 1999 | Founding Date 1896 | Founding Date 1996 | Founding Date 1849 | Founding Date 2000 | Founding Date 1886 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Osaka, JP HQ Beijing, CN Hong Kong, HK Amagasaki, JP Amagasaki, JP Kanegasaki, JP Misato, JP see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Bentley, AU Footscray, AU Mulgrave, AU Sydney, AU see more | Locations Brentford, GB HQ Boumerdes, DZ San Fernando, AR Abbotsford, AU Boronia, AU Ermington, AU Wien, AT see more | Locations New Brunswick, US HQ Buenos Aires, AR Sydney, AU Ultimo, AU Wien, AT Minsk, BY Beerse, BE see more | ||
Employees | Employees 94,2454% decrease | Employees 4,959 | Employees 14,754 | Employees 89,900 | Employees 103,605 | Employees 76,057 | Employees 83,0005% increase | Employees 70,212 | Employees 131,90014% decrease |
Valuation ($) | Valuation ($) 27.1 b | Valuation ($) 12.3 b | Valuation ($) 20.8 b | Valuation ($) 2.7 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 163.9 b | Valuation ($) 862.5 m | Valuation ($) 396.3 b |
Financial | |||||||||
Revenue (est.) | Revenue (est.) €47.6b (FY, 2023) | Revenue (est.) ¥410.1b (FY, 2024) | Revenue (est.) ¥1.6t (FY, 2024) | Revenue (est.) $45.8b (FY, 2023) | Revenue (est.) CHF58.7b (FY, 2023) | Revenue (est.) $54.1b (FY, 2023) | Revenue (est.) $58.5b (FY, 2023) | Revenue (est.) £30.3b (FY, 2023) | Revenue (est.) $85.2b (FY, 2023) |
Cost of goods | Cost of goods €7b (FY, 2023) | Cost of goods ¥39.3b (FY, 2024) | Cost of goods ¥134.6b (FY, 2024) | Cost of goods $7.2b (FY, 2023) | Cost of goods CHF12.4b (FY, 2023) | Cost of goods $8.2b (FY, 2023) | Cost of goods $25b (FY, 2023) | Cost of goods £5.8b (FY, 2023) | Cost of goods $26.6b (FY, 2023) |
Gross profit | Gross profit €42.1b (FY, 2023) | Gross profit ¥395.8b (FY, 2024) | Gross profit ¥1.5t (FY, 2024) | Gross profit $39.8b (FY, 2023) | Gross profit CHF48.5b (FY, 2023) | Gross profit $47.7b (FY, 2023) | Gross profit $33.5b (FY, 2023) | Gross profit £25.7b (FY, 2023) | Gross profit $58.6b (FY, 2023) |
Net income | Net income (€2.9b) (FY, 2023) | Net income ¥160.6b (FY, 2024) | Net income ¥17b (FY, 2024) | Net income $6b (FY, 2023) | Net income CHF12.4b (FY, 2023) | Net income $9b (FY, 2023) | Net income $2.2b (FY, 2023) | Net income £5.3b (FY, 2023) | Net income $35.2b (FY, 2023) |
Operating ⚠ | |||||||||
Countries | Countries 83 (FY, 2021) | Countries N/A | Countries N/A | Countries 130 (FY, 2021) | Countries N/A | Countries N/A | Countries 125 (FY, 2021) | Countries 92 (FY, 2021) | Countries N/A |
Patients | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients 22.8 m (FY, 2023) | Patients 10 m (FY, 2022) | Patients N/A | Patients N/A | Patients N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 27 (FY, 2021) | Phase I Trials Products 16 (FY, 2021) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 25 (FY, 2021) | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 27 (FY, 2021) | Phase III Trials Products 11 (FY, 2021) | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 10 (FY, 2021) | Registration Phase Products N/A | Registration Phase Products N/A |
Suppliers | Suppliers 93.8 k (FY, 2021) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 37.5 k (FY, 2021) | Suppliers N/A |
Funding | |||||||||
Total funding raised | Total funding raised $ 3.5b | Total funding raised $ 4.7m | Total funding raised N/A | Total funding raised $ 1b | Total funding raised $ 7.8b | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Shionogi
HQ
Osaka, JP
Employees
4,959
Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases.
View companyAstellas Pharma
HQ
Tokyo, JP
Employees
14,754
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
View companyAstraZeneca
HQ
Cambridge, GB
Employees
89,900
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
View companyRoche
HQ
Basel, CH
Employees
103,605
Roche Holding is a biotech company that provides in-vitro diagnostics and supplies solutions across various disease areas.
View company